A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation.
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2017
At a glance
- Drugs ICT 107 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors ImmunoCellular Therapeutics
- 21 Nov 2016 Results published in an ImmunoCellular Therapeutics Media Release.
- 21 Nov 2016 According to an ImmunoCellular Therapeutics media release, updated immune monitoring data from this trial at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
- 22 Aug 2016 According to an ImmunoCellular Therapeutics media release, the company plans to present immune monitoring data from this trial at the Society for NeuroOncology Annual Scientific Meeting 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History